COSENTYX (secukinumab)

Self-administration – Subcutaneous (SC) injection may be given at home by the UnoReady pen, Sensoready pen, and prefilled syringe.

Office-administration – Solution in vials is for healthcare professional use only.

 

Indications for Prior Authorization:

 

Plaque Psoriasis (PsO): Indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis (PsA): Indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older.

Ankylosing Spondylitis (AS): Indicated for the treatment of adult patients with active ankylosing spondylitis.

Non-radiographic axial spondyloarthritis (nr-axSpA): Indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Enthesitis-related arthritis (ERA): Indicated for the treatment of active enthesitis-related arthritis in patients 4 years of age and older.

Hidradenitis Suppurativa (HS): Indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).

 

Coverage Criteria:

 

For diagnosis of plaque psoriasis (PsO):

  • Documented diagnosis of moderate to severe PsO; AND
  • Patient is 6 years of age or older; AND
  • One of the following:
    • Greater than or equal to 3% body surface area involvement 
    • Severe scalp psoriasis 
    • Palmoplantar (i.e., palms, soles), facial, or genital involvement; AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a minimum duration of a 4-week trial and failure, contraindication, or intolerance to one of the following topical therapies: 
    • corticosteroids (e.g., betamethasone, clobetasol) 
    • vitamin D analogs (e.g., calcitriol, calcipotriene) 
    • tazarotene 
    • calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) 
    • anthralin 
    • coal tar; AND
  • Prescribed by or in consultation with a dermatologist; AND
  • Both of the following:
    • One of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to THREE of the following: 
        • Cimzia (certolizumab pegol) 
        • Enbrel (etanercept) 
        • Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz  
        • Skyrizi (risankizumab) 
        • Stelara (ustekinumab) 
        • Tremfya (guselkumab)
      • Both of the following:
        • Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Cosentyx therapy, defined as no more than a 45-day gap in therapy
        • Documentation of positive clinical response to therapy as evidenced by ONE of the following:
          • Reduction the body surface area (BSA) involvement from baseline 
          • Improvement in symptoms (e.g., pruritus, inflammation) from baseline
    • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to Taltz (ixekizumab).

 

For diagnosis of psoriatic arthritis (PsA):

  • Documented diagnosis of active PsA; AND
  • One of the following:
    • actively inflamed joints 
    • dactylitis 
    • enthesitis 
    • axial disease 
    • active skin and/or nail involvement; AND
  • Patient is 2 years of age or older; AND
  • Prescribed by or in consultation with a rheumatologist or dermatologist; AND
  • One of the following:
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to TWO of the following: 
        • Cimzia (certolizumab pegol)
        • Enbrel (etanercept)
        • Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz
        • Simponi (golimumab)
        • Stelara (ustekinumab)
        • Tremfya (guselkumab)
        • Skyrizi (risankizumab-rzaa)
        • Rinvoq (upadacitinib)
        • Xeljanz/XR (tofacitinib/ER)
      • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to BOTH of the following:
        • Taltz (ixekizumab)
        • Orencia (abatacept) 
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Cosentyx therapy, defined as no more than a 45-day gap in therapy
      • Documentation of positive clinical response to therapy as evidenced by at least one of the following:
        • Reduction in the total active (swollen and tender) joint count from baseline 
        • Improvement in symptoms (e.g., pain, stiffness, pruritus, inflammation) from baseline.
        • Reduction in the body surface area (BSA) involvement from baseline.

 

For diagnosis of ankylosing spondylitis (AS):

  • Documented diagnosis of active AS; AND
  • Prescribed by or in consultation with a rheumatologist; AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a minimum duration of one-month trial and failure, contraindication, or intolerance to TWO different nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen, indomethacin, meloxicam, diclofenac) at maximally tolerated doses; AND
  • One of the following:
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to TWO of the following, or attestation demonstrating a trial may be inappropriate*: 
        • Cimzia (certolizumab pegol)
        • Enbrel (etanercept)
        • Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz
        • Simponi (golimumab)
        • Rinvoq (upadacitinib)
        • Xeljanz/XR (tofacitinib/ER)
      • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to Taltz (ixekizumab).
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Cosentyx therapy, defined as no more than a 45-day gap in therapy
      • Documentation of positive clinical response to therapy as evidenced by improvement from baseline for least one of the following:
        • Disease activity (e.g., pain, fatigue, inflammation, stiffness) 
        • Lab values (erythrocyte sedimentation rate, C-reactive protein level) 
        • Function 
        • Axial status (e.g., lumbar spine motion, chest expansion) 
        • Total active (swollen and tender) joint count

*Includes attestation that a total of two TNF inhibitors have already been tried in the past, and the patient should not be made to try a third TNF inhibitor.

 

For diagnosis of Non-radiographic Axial Spondyloarthritis (nr-axSpA):

  • Documented diagnosis of active nr-axSpA; AND
  • Prescribed by or in consultation with a rheumatologist; AND
  • Patient has objective signs of inflammation (e.g. C-reactive protein [CRP] levels above the upper limit of normal, or sacroiliitis on magnetic resonance imaging [MRI], indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints); AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a minimum duration of one-month trial and failure, contraindication, or intolerance to TWO different nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen, indomethacin, meloxicam, diclofenac) at maximally tolerated doses; AND
  • One of the following:
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to ALL of the following:
        • Cimzia (certolizumab pegol) 
        • Rinvoq (upadacitinib)† 
        • Taltz (ixekizumab)
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Cosentyx therapy, defined as no more than a 45-day gap in therapy
      • Documentation of positive clinical response to therapy as evidenced by improvement from baseline for least one of the following:
        • Disease activity (e.g., pain, fatigue, inflammation, stiffness) 
        • Lab values (erythrocyte sedimentation rate, C-reactive protein level) 
        • Function 
        • Axial status (e.g., lumbar spine motion, chest expansion) 
        • Total active (swollen and tender) joint count

† Requires inadequate response or intolerance to one or more TNF-inhibitors.

 

For diagnosis of enthesitis-related arthritis (ERA):

  • Documented diagnosis of active ERA; AND
  • Patient is 4 years of age or older; AND
  • Prescribed by or in consultation with a rheumatologist; AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a minimum duration of one-month trial and failure, contraindication, or intolerance to TWO different nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen, indomethacin, meloxicam, diclofenac) at maximally tolerated doses.

 

For diagnosis of hidradenitis suppurativa (HS):

  • Diagnosis of moderate to severe hidradenitis suppurativa; AND
  • Prescribed by or in consultation with a dermatologist; AND
  • One of the following:
    • Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz, or Brand Adalimumab-adaz
    • Both of the following:
      • Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Cosentyx therapy, defined as no more than a 45-day gap in therapy
      • Documentation of positive clinical response to therapy

 

Reauthorization Criteria:

 

For diagnosis of PsO:

  • Documentation of a positive clinical response to therapy as evidenced by ONE of the following:
    • Reduction the body surface area (BSA) involvement from baseline
    • Improvement in symptoms (e.g., pruritus, inflammation) from baseline

 

For diagnosis of PsA:

  • Documentation of a positive clinical response to therapy as evidenced by at least one of the following: 
    • Reduction in the total active (swollen and tender) joint count from baseline
    • Improvement in symptoms (e.g., pain, stiffness, pruritus, inflammation) from baseline
    • Reduction in the body surface area (BSA) involvement from baseline

 

For diagnosis of AS:

  • Documentation of a positive clinical response to therapy as evidenced by improvement from baseline for least one of the following: 
    • Disease activity (e.g., pain, fatigue, inflammation, stiffness)
    • Lab values (erythrocyte sedimentation rate, C-reactive protein level)
    • Function
    • Axial status (e.g., lumbar spine motion, chest expansion)
    • Total active (swollen and tender) joint count 

 

For diagnosis of nr-axSpA:

  • Documentation of a positive clinical response to therapy as evidenced by improvement from baseline for least one of the following: 
    • Disease activity (e.g., pain, fatigue, inflammation, stiffness)
    • Lab values (erythrocyte sedimentation rate, C-reactive protein level)
    • Function
    • Axial status (e.g., lumbar spine motion, chest expansion)
    • Total active (swollen and tender) joint count

 

For diagnosis of ERA:

  • Documentation of a positive clinical response to therapy as evidenced by at least one of the following:
    • Reduction in the total active (swollen and tender) joint count from baseline
    • Improvement in symptoms (e.g., pain, stiffness, inflammation) from baseline

 

For diagnosis of HS:

  • Patient demonstrates positive clinical response to therapy

 

Dosing:

 

PsO:

  • Adults: 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks
  • Pediatrics, age 6-17 years (50 kg or more): 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks
  • Pediatrics, age 6-17 years (less than 50 kg): 75 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 75 mg every 4 weeks

PsA:

  • Adults: 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by up to 300 mg every 4 weeks thereafter
  • Pediatrics, age 2-17 years (50 kg or more): 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks
  • Pediatrics, age 2-17 years (l5kg to 49 kg): 75 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 75 mg every 4 weeks
  • For PsA patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis

AS:

  • 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by up to 300 mg every 4 weeks thereafter

Non-radiographic axial spondyloarthritis (nr-axSpA):

  • 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by up to 150 mg every 4 weeks thereafter

ERA:

  • Patients weighing 15 kg to less than 50 kg: 75 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
  • Patients weighing 50 kg or more: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter

HS:

  • 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter
  • If a patient does not adequately respond, consider increasing the dosage to 300 mg every 2 weeks. Each 300 mg dosage is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg

 

Coverage Duration:

For diagnosis of PsO, PsA, AS, nr-axSpA, or ERA:

  • Initial: 1 year
  • Reauthorization: 1 year

For diagnosis of HS:

  • Initial: 6 months
  • Reauthorization: 1 year

 

Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

 

Additional Information:
  • Patients should be tested for latent tuberculosis (TB) (e.g. TB skin test, QuantiFERON TB Gold test, or chest x-ray) before Cosentyx use and during therapy. Treatment for latent infection should be initiated prior to Cosentyx use.
  • Axial disease involvement affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis.

 

Policy Updates:
  • 07/01/2020 - Annual review.
  • 11/16/2021 - Added coverage criteria for nr-axSpA; updated format.
  • 04/05/2022 - New criteria for new indication of ERA. Addition of additional preferred agents for PsA.
  • 08/16/2022 - Update AS criteria to include all WHA preferred agents for the treatment of AS. 
  • 01/01/2023 - Addition of Enbrel as an additional preferred step option for PsO, PsA, and AS. Further clinical detail and criteria added.
  • 09/01/2023 - Addition of Amjevita, Cyltezo, Hyrimoz, and brand Adalimumab-adaz as preferred options for PsO, PsA, and AS. (P&T 08/15/2023).
  • 11/14/2023 – Update Hyrimoz preferred agent to Sandoz manufacturer only. (P&T, 11/14/2023)
  • 12/18/2023 — New criteria for new indication of HS (P&T vote, 12/18/23)

 

References:
  1. Cosentyx prescribing information. Novartis Pharmaceuticals Corp. East Hanover, NJ. October 2023. 
  2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72. 
  3. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70. 
  4. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32. 
  5. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613. 
  6. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. 2019;71(6):717-734. 

Last review date: December 18, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone